Form 4: Kezar Life Sciences Director Micki Klearman Granted 5,000 Stock Options

Kezar Life Sciences, Inc. Director Micki Klearman was granted 5,000 stock options with an exercise price of $4.46 per share, vesting in June 2026.

Summary

• Micki Klearman, a Director of Kezar Life Sciences, Inc. (KZR), was granted 5,000 stock options.
• The transaction date for this grant was June 18, 2025.
• Each stock option has an exercise price of $4.46.
• The options are scheduled to vest 100% on June 18, 2026, contingent upon Ms. Klearman's continued service to the company.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Ms. Klearman beneficially owns 5,000 derivative securities directly.

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options to a director aligns their interests with shareholders and is a common incentive, indicating continued engagement.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• It indicates continued commitment and incentivization for the director's service to the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and life sciences industry, serving as a form of long-term incentive compensation and a mechanism to align the interests of board members with those of shareholders. This particular grant is a routine compensation event for a director.

Related Party Transactions

• The grant of stock options to a director is inherently a related party transaction, representing compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options become more valuable if the stock price increases.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options are scheduled to vest on June 18, 2026, subject to the director's continued service.

Key Dates

Keywords

Kezar Life Sciences, KZR, Stock Option, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership